Logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
Saturday, July 11, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Policy
Oncology Without Borders
About Us
  • Contributors
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan

Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan

July 9, 2026

Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives

Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives

July 8, 2026

Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist

Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist

July 3, 2026

Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist

Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist

July 2, 2026

Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results

Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results

July 1, 2026

Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia

Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia

HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer

HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer

Share Article

Get the Quick Bites delivered to your inbox daily

Logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved